Pub Date : 2026-03-11DOI: 10.1186/s12943-026-02635-4
Cuilan Li, Vincent Ws Liu, Pui Man Chiu, Kwok-Ming Yao, Hextan Ys Ngan, David W Chan
{"title":"Retraction Note: Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer.","authors":"Cuilan Li, Vincent Ws Liu, Pui Man Chiu, Kwok-Ming Yao, Hextan Ys Ngan, David W Chan","doi":"10.1186/s12943-026-02635-4","DOIUrl":"10.1186/s12943-026-02635-4","url":null,"abstract":"","PeriodicalId":19000,"journal":{"name":"Molecular Cancer","volume":"25 1","pages":""},"PeriodicalIF":33.9,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12977475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147434344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pancreatic ductal adenocarcinoma (PDAC) continues to rank among the most lethal malignancies, with five-year survival rates stubbornly below 12%. Over the past decade and a half, transcriptomic analyses have consistently identified molecular subtypes - particularly the classical/progenitor (GATA6-high) and basal-like/squamous (GATA6-low) - that show clear associations with prognosis and treatment response. Yet, despite compelling biological rationale, the clinical adoption of these subtypes has been constrained by limited reproducibility, technical challenges, and practical barriers to implementation. Recent progress in multi-omics integration has deepened our understanding of subtype biology, while also exposing new layers of complexity in classification frameworks. A pivotal study demonstrated that a straightforward immunohistochemical assessment of GATA6 provides strong prognostic information in treatment-naive patients. However, it also underscored a critical challenge: therapy-induced molecular plasticity can compromise the reliability of static biomarkers. Advances in single-cell RNA sequencing and spatial transcriptomics have further clarified the cellular and microenvironmental dynamics underlying subtype heterogeneity, offering new insights on immune contexture and therapeutic stratification. In this review, we synthesize key developments in PDAC subtyping, critically examine translational hurdles, and propose a pragmatic roadmap for clinical implementation that prioritizes validated simplicity, contextual relevance, and real-world utility.
{"title":"Molecular subtypes in pancreatic cancer: from academic promise to clinical reality.","authors":"Daniela Mercedes D'Empaire Altimari,Michele Bevere,Elisa Espinet,Yvan Martineau,Elisa Giovannetti,Víctor Javier Sánchez-Arévalo Lobo","doi":"10.1186/s12943-026-02614-9","DOIUrl":"https://doi.org/10.1186/s12943-026-02614-9","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) continues to rank among the most lethal malignancies, with five-year survival rates stubbornly below 12%. Over the past decade and a half, transcriptomic analyses have consistently identified molecular subtypes - particularly the classical/progenitor (GATA6-high) and basal-like/squamous (GATA6-low) - that show clear associations with prognosis and treatment response. Yet, despite compelling biological rationale, the clinical adoption of these subtypes has been constrained by limited reproducibility, technical challenges, and practical barriers to implementation. Recent progress in multi-omics integration has deepened our understanding of subtype biology, while also exposing new layers of complexity in classification frameworks. A pivotal study demonstrated that a straightforward immunohistochemical assessment of GATA6 provides strong prognostic information in treatment-naive patients. However, it also underscored a critical challenge: therapy-induced molecular plasticity can compromise the reliability of static biomarkers. Advances in single-cell RNA sequencing and spatial transcriptomics have further clarified the cellular and microenvironmental dynamics underlying subtype heterogeneity, offering new insights on immune contexture and therapeutic stratification. In this review, we synthesize key developments in PDAC subtyping, critically examine translational hurdles, and propose a pragmatic roadmap for clinical implementation that prioritizes validated simplicity, contextual relevance, and real-world utility.","PeriodicalId":19000,"journal":{"name":"Molecular Cancer","volume":"6 1","pages":""},"PeriodicalIF":37.3,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147373828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：